Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3 | Zendy

Cheng-Shi He | Zendy; Yicheng Liu | Zendy; Zhipeng Xu | Zendy; Peng-Chen Dai | Zendy; Xiaowei Chen | Zendy; De-Hai Jin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3

Author(s) -

Cheng-Shi He,

Yicheng Liu,

Zhipeng Xu,

Peng-Chen Dai,

Xiaowei Chen,

De-Hai Jin

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000453175

Subject(s) - cisplatin , cytotoxicity , lung cancer , pharmacology , viability assay , chemotherapy , cancer research , in vitro , medicine , chemistry , oncology , biochemistry

Chemoresistance is a major obstacle to successful chemotherapy for human non-small cell lung cancer (NSCLC). Astragaloside IV, the component of Astragalus membranaceus, has been reported to exhibit anti-inflammation, anti-cancer and immunoregulatory properties. In the present study, we investigated the role of astragaloside IV in the chemoresistance to cisplatin in NSCLC cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research